Long-term survival after immunotherapy and targeted therapy without chemotherapy in an elderly patient with HER2-positive gastroesophageal junction cancer: A case report-Reference-Cited by-同舟云学术

Long-term survival after immunotherapy and targeted therapy without chemotherapy in an elderly patient with HER2-positive gastroesophageal junction cancer: A case report

Published:2022-09-27 Issue:6 Volume:18 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Li Wei-Ling¹²,Zhang Ying¹²,Zhang Xiao-Ling¹,Du Yun-Yi¹,Hu Wen-Qing³,Zhao Jun¹

Affiliation:

1. Department of Oncology, Changzhi People’s Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China

2. Graduate School, Changzhi Medical College, Changzhi, Shanxi, China

3. Department of Gastrointestinal Surgery, Changzhi People’s Hospital Affiliated to Changzhi Medical College, Changzhi, China

Funder

funding associated

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2022.2121109

Reference20 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

3. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

4. FDA Approves Merck’s KEYTRUDA® (pembrolizumab). Combined with trastuzumab and chemotherapy as first-line treatment in locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

5. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases;Diagnostics;2023-03-25

2. Multiple drugs;Reactions Weekly;2023-01-21